FDA’s Rasonque review documents pressure RevMed as investors jitter over KRAS subgroup data - Fierce Pharma

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQUzZEeHBQMTRWUWxKV3…; target="_blank">FDA’s Rasonque review documents pressure RevMed as investors jitter over KRAS subgroup data</a>&nbsp;&nbsp;<font color="#6f6f6f">Fierce Pharma</font>